Havanka-Kanniainen H, Hokkanen E, Myllylä V V
Cephalalgia. 1985 Mar;5(1):39-43. doi: 10.1046/j.1468-2982.1985.0501039.x.
The efficacy of nimodipine in the prophylaxis of migraine was assessed in a double-blind, placebo-controlled, cross-over study carried out on 33 patients, 20 of whom suffered from classic and 13 from common migraine. Four patients dropped out, but not as a result of the side effects of the drug. The duration of drug treatment was 8 weeks. The dosage used was 30 mg four times daily. Nimodipine proved to be better than placebo, the number of migraine attacks and severity of headache showing a significant reduction. The drug was well tolerated and no marked side effects were noted. The results suggest that nimodipine is a useful new prophylactic drug for migraine, but further studies are needed before its final value can be evaluated.
在一项针对33例患者开展的双盲、安慰剂对照、交叉研究中，评估了尼莫地平预防偏头痛的疗效。其中20例患有典型偏头痛，13例患有普通偏头痛。4例患者退出研究，但并非因药物副作用所致。药物治疗持续时间为8周。使用的剂量为每日4次，每次30毫克。结果证明尼莫地平优于安慰剂，偏头痛发作次数和头痛严重程度均显著降低。该药物耐受性良好，未观察到明显副作用。结果表明，尼莫地平是一种用于预防偏头痛的有效新药，但在评估其最终价值之前还需要进一步研究。
